Cargando…

Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel

BACKGROUND: Heat Shock Transcription Factor 1 (HSF1) is activated under stress conditions. In turn, it induces expression of Heat Shock Proteins (HSPs), which are well-known regulators of protein homeostasis. Elevated levels of HSF1 and HSPs were observed in many types of tumors. The aim of the pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Vydra, Natalia, Toma, Agnieszka, Glowala-Kosinska, Magdalena, Gogler-Piglowska, Agnieszka, Widlak, Wieslawa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231344/
https://www.ncbi.nlm.nih.gov/pubmed/24165036
http://dx.doi.org/10.1186/1471-2407-13-504
_version_ 1782344429265223680
author Vydra, Natalia
Toma, Agnieszka
Glowala-Kosinska, Magdalena
Gogler-Piglowska, Agnieszka
Widlak, Wieslawa
author_facet Vydra, Natalia
Toma, Agnieszka
Glowala-Kosinska, Magdalena
Gogler-Piglowska, Agnieszka
Widlak, Wieslawa
author_sort Vydra, Natalia
collection PubMed
description BACKGROUND: Heat Shock Transcription Factor 1 (HSF1) is activated under stress conditions. In turn, it induces expression of Heat Shock Proteins (HSPs), which are well-known regulators of protein homeostasis. Elevated levels of HSF1 and HSPs were observed in many types of tumors. The aim of the present study was to determine whether HSF1 could have an effect on the survival of cancer cells treated with chemotherapeutic cytotoxic agents. METHODS: We constructed mouse (B16F10) and human (1205Lu, WM793B) melanoma cells overexpressing full or mutant form of human HSF1: a constitutively active one with a deletion in regulatory domain or a dominant negative one with a deletion in the activation domain. The impact of different forms of HSF1 on the expression of HSP and ABC genes was studied by RT-PCR and Western blotting. Cell cultures were treated with increasing amounts of doxorubicin, paclitaxel, cisplatin, vinblastine or bortezomib. Cell viability was determined by MTT, and IC(50) was calculated. Cellular accumulation of fluorescent dyes and side population cells were studied using flow cytometry. RESULTS: Cells overexpressing HSF1 and characterized by increased HSPs accumulation were more resistant to doxorubicin or paclitaxel, but not to cisplatin, vinblastine or bortezomib. This resistance correlated with the enhanced efflux of fluorescent dyes and the increased number of side population cells. The expression of constitutively active mutant HSF1, also resulting in HSPs overproduction, did not reduce the sensitivity of melanoma cells to drugs, unlike in the case of dominant negative form expression. Cells overexpressing a full or dominant negative form of HSF1, but not a constitutively active one, had higher transcription levels of ABC genes when compared to control cells. CONCLUSIONS: HSF1 overexpression facilitates the survival of melanoma cells treated with doxorubicin or paclitaxel. However, HSF1-mediated chemoresistance is not dependent on HSPs accumulation but on an increased potential for drug efflux by ABC transporters. Direct transcriptional activity of HSF1 is not necessary for increased expression of ABC genes, which is probably mediated by HSF1 regulatory domain.
format Online
Article
Text
id pubmed-4231344
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42313442014-11-15 Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel Vydra, Natalia Toma, Agnieszka Glowala-Kosinska, Magdalena Gogler-Piglowska, Agnieszka Widlak, Wieslawa BMC Cancer Research Article BACKGROUND: Heat Shock Transcription Factor 1 (HSF1) is activated under stress conditions. In turn, it induces expression of Heat Shock Proteins (HSPs), which are well-known regulators of protein homeostasis. Elevated levels of HSF1 and HSPs were observed in many types of tumors. The aim of the present study was to determine whether HSF1 could have an effect on the survival of cancer cells treated with chemotherapeutic cytotoxic agents. METHODS: We constructed mouse (B16F10) and human (1205Lu, WM793B) melanoma cells overexpressing full or mutant form of human HSF1: a constitutively active one with a deletion in regulatory domain or a dominant negative one with a deletion in the activation domain. The impact of different forms of HSF1 on the expression of HSP and ABC genes was studied by RT-PCR and Western blotting. Cell cultures were treated with increasing amounts of doxorubicin, paclitaxel, cisplatin, vinblastine or bortezomib. Cell viability was determined by MTT, and IC(50) was calculated. Cellular accumulation of fluorescent dyes and side population cells were studied using flow cytometry. RESULTS: Cells overexpressing HSF1 and characterized by increased HSPs accumulation were more resistant to doxorubicin or paclitaxel, but not to cisplatin, vinblastine or bortezomib. This resistance correlated with the enhanced efflux of fluorescent dyes and the increased number of side population cells. The expression of constitutively active mutant HSF1, also resulting in HSPs overproduction, did not reduce the sensitivity of melanoma cells to drugs, unlike in the case of dominant negative form expression. Cells overexpressing a full or dominant negative form of HSF1, but not a constitutively active one, had higher transcription levels of ABC genes when compared to control cells. CONCLUSIONS: HSF1 overexpression facilitates the survival of melanoma cells treated with doxorubicin or paclitaxel. However, HSF1-mediated chemoresistance is not dependent on HSPs accumulation but on an increased potential for drug efflux by ABC transporters. Direct transcriptional activity of HSF1 is not necessary for increased expression of ABC genes, which is probably mediated by HSF1 regulatory domain. BioMed Central 2013-10-29 /pmc/articles/PMC4231344/ /pubmed/24165036 http://dx.doi.org/10.1186/1471-2407-13-504 Text en Copyright © 2013 Vydra et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Vydra, Natalia
Toma, Agnieszka
Glowala-Kosinska, Magdalena
Gogler-Piglowska, Agnieszka
Widlak, Wieslawa
Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title_full Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title_fullStr Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title_full_unstemmed Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title_short Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
title_sort overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231344/
https://www.ncbi.nlm.nih.gov/pubmed/24165036
http://dx.doi.org/10.1186/1471-2407-13-504
work_keys_str_mv AT vydranatalia overexpressionofheatshocktranscriptionfactor1enhancestheresistanceofmelanomacellstodoxorubicinandpaclitaxel
AT tomaagnieszka overexpressionofheatshocktranscriptionfactor1enhancestheresistanceofmelanomacellstodoxorubicinandpaclitaxel
AT glowalakosinskamagdalena overexpressionofheatshocktranscriptionfactor1enhancestheresistanceofmelanomacellstodoxorubicinandpaclitaxel
AT goglerpiglowskaagnieszka overexpressionofheatshocktranscriptionfactor1enhancestheresistanceofmelanomacellstodoxorubicinandpaclitaxel
AT widlakwieslawa overexpressionofheatshocktranscriptionfactor1enhancestheresistanceofmelanomacellstodoxorubicinandpaclitaxel